Advertisement

Real-life use of isavuconazole outside the hematological wards

Published:September 13, 2019DOI:https://doi.org/10.1016/j.ejim.2019.09.005
      Real-world data on efficacy and safety of isavuconazole (ISV) are mostly based on cohorts of patients with hematological malignancies, stem cells or solid organ transplants (i.e., HSCT or SOT) [
      • Hoenigl M
      • Prattes J
      • Neumeister P
      • Wölfler A
      • Krause R
      Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: an illustrative case study.
      ,
      • DiPippo AJ
      • Kontoyiannis DP
      Lack of toxicity with long term isavuconazole use in patients with hematologic malignancy.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hoenigl M
        • Prattes J
        • Neumeister P
        • Wölfler A
        • Krause R
        Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: an illustrative case study.
        Mycoses. 2018; 61: 201-205
        • DiPippo AJ
        • Kontoyiannis DP
        Lack of toxicity with long term isavuconazole use in patients with hematologic malignancy.
        Clin Infect Dis. 2019; ([2019 Mar 7. pii: ciz159])https://doi.org/10.1093/cid/ciz159
        • Russo A
        • Falcone M
        • Vena A
        • Vena A
        • Venditti C
        • Mancini C
        • et al.
        Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience.
        J Chemother. 2011; 23: 290-294
        • Bassetti M
        • Bouza E
        Invasive mould infections in the ICU setting: complexities and solutions.
        J Antimicrob Chemother. 2017; 72: i39-i47
        • De Pauw B
        • Walsh TJ
        • Donnelly JP
        • et al.
        European Organization for Research and Treatment of cancer/InvasiveFungal infections cooperative group. Revised definitions of invasive fungal dis- ease from the European Organization for Research and Treatment of cancer/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC/MSG) consensus group. National Institute of Allergy and Infectious Diseases mycoses study group (EORTC/MSG) consensus group.
        Clin Infect Dis. 2008; 46: 1813-1821
        • Blot SI
        • Taccone FS
        • Van den Abeele AM
        • Bulpa P
        • Meersseman W
        • Brusselaers N
        • et al.
        A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients.
        Am J Respir Crit Care Med. 2012; 186: 56-64
        • Bassetti M
        • Peghin M
        • Vena A
        Challenges and solution of invasive Aspergillosis in non-neutropenic patients: a review.
        Infect Dis Ther. 2018; 7: 17-27
        • Danion F
        • Rouzaud C
        • Duréault A
        • Poirée S
        • Bougnoux ME
        • Alanio A
        Why are so many cases of invasive aspergillosis missed?.
        Med Mycol. 2019; 57: S94-S103
        • Meersseman W
        • Lagrou K
        • Maertens J
        • et al.
        Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients.
        Am J Respir Crit Care Med. 2008; 177: 27-34